ZS Pharma, Inc

From manufacturing to technology to people, ZS Pharma is thinking differently about developing therapies to address unmet needs. ZS Pharma was founded in 2008, became a public company in 2014 and, in December 2015, joined the AstraZeneca Group. We are a biopharmaceutical company dedicated to challenging the status quo in disease areas where therapeutic options have been limited. We are currently focused on using our proprietary ion-trap technology to develop new treatments. The ZS Pharma team combines deep knowledge and experience with an unparalleled drive to provide innovative new medicines for patients, families and physicians facing serious, difficult-to-treat diseases. We are developing new options in treating ion imbalances, and are currently executing a robust clinical development program for our first product candidate: ZS-9 for the treatment of hyperkalemia. Hyperkalemia, or high serum potassium, results in serious clinical complications in both acute and chronic settin...